Santhera Pharmaceutical Holding Ltd

Santhera Pharmaceuticals

Santhera is focusing on the development and commercialization of innovative treatments of mitochondrial and neuromuscular diseases. This area of high unmet medical need includes many orphan and niche indications with no current therapy. Strategically, Santhera focuses on RaxoneŽ/CatenaŽ (INN: idebenone) in mutliple indications.

Products & Pipeline

Santhera has a late-stage development pipeline in orphan indications. The lead compound RaxoneŽ/CatenaŽ (INN: idebenone) is being developed in three indications: Leber's Hereditary Optic Neuropathy, Duchenne Muscular Dystrophy, and Primary Progressive Multiple Sclerosis.

Clinical Development Programs

Currently, the NIH are investigating the safety and efficacy of RaxoneŽ/CatenaŽ in a Phase II trial (IPPoMS) as potential therapy of primary progressive Multiple Sclerosis. Also at the NIH, a Phase I study (CALLISTO) is being initiated to investigate the omigapil in pediatric and adolescent patients suffering from Congenital Muscular Dystrophy.

Latest News

September 09, 2014
Santhera Reports First Half 2014 Financial Results and Positive Developments in All Strategic Program
---
August 15, 2014
Santhera Receives CHF 13.4 Million Through Sale of Treasury Shares
---
July 17, 2014
Santhera Repositions Omigapil in Congenital Muscular Dystrophy and Initiates Clinical Development Program with Public-Private Partners